Report results from the TRANQUILITY trial
Delivered after the deadline (217 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 7 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- 5 Aug 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Results from TRANQUILITY are expected in the second half of 2021.”
What we found
Evidence strength A What the grades mean
The company announced positive results from the Phase 3 TRANQUILITY-2 trial on August 5, 2022, which is after the mid-2022 deadline.
-
A Aldeyra Therapeutics, Inc. 8-K filed 2022-08-05
“Positive Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease: Reproxalap was statistically superior to vehicle for each of the two prespecified primary endpoints” ✓ confirmed on the page
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +365 days
- 2 versions
-
Version 1 · original · stated 7 Jan 2021
Deadline 31 Dec 2021 (“in the second half of 2021”) · wording expected
-
Version 2 · stated 29 Mar 2022
Deadline 31 Dec 2022 (“in the second half of 2022”) · wording expected
“Results from the ethanol toxicity trial are expected in the second half of 2022”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- TRANQUILITY trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALDX-021258 · Corrections policy